Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Enrico Mini

Showing results (101-110 of 134) with videos related to

Pageof 14
Sort By:
Journal of Medicinal Chemistry|January 15, 2009
N,N-bis(cyclohexanol)amine aryl esters: a new class of highly potent transporter-dependent multidrug resistance inhibitorsCecilia Martelli, Daniela Alderighi, Marcella Coronnello, et al.
ACS Medicinal Chemistry Letters|April 19, 2019
Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian CancerTiziano Marzo, Lara Massai, Alessandro Pratesi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2009
Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancerGiuseppe Toffoli, Erika Cecchin, Giampiero Gasparini, et al.
Annals of Nuclear Medicine|October 30, 2022
Added prognostic value of molecular imaging parameters over proliferation index in typical lung carcinoid: an [18F]FDG PET/CT and SSTR imaging studyFlavia Linguanti, Elisabetta M Abenavoli, Vittorio Briganti, et al.
Oncology Research|August 24, 2006
Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedulesAlessio Tempestini, Barbara Caciagli, Maria Morganti, et al.
Medycyna Pracy|November 14, 2022
Monitoring surface contamination for thirty antineoplastic drugs: a new proposal for surface exposure levels (SELs)Stefano Dugheri, Nicola Mucci, Elisabetta Bucaletti, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2005
Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancersMaria Morganti, Monica Ciantelli, Beatrice Giglioni, et al.
JAMA Oncology|January 16, 2016
Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 TrialJulien Taieb, Aziz Zaanan, Karine Le Malicot, et al.
International Journal of Cancer|April 12, 2019
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapyEnrico Mini, Andrea Lapucci, Gabriele Perrone, et al.
European Journal of Cancer (Oxford, England : 1990)|August 19, 2008
Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)Ivan Popov, Alfredo Carrato, Alberto Sobrero, et al.
Pageof 14

Showing results (101-110 of 134) with videos related to

Sort By:
Pageof 14
Journal of Medicinal Chemistry|January 15, 2009
N,N-bis(cyclohexanol)amine aryl esters: a new class of highly potent transporter-dependent multidrug resistance inhibitorsCecilia Martelli, Daniela Alderighi, Marcella Coronnello, et al.
ACS Medicinal Chemistry Letters|April 19, 2019
Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian CancerTiziano Marzo, Lara Massai, Alessandro Pratesi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2009
Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancerGiuseppe Toffoli, Erika Cecchin, Giampiero Gasparini, et al.
Annals of Nuclear Medicine|October 30, 2022
Added prognostic value of molecular imaging parameters over proliferation index in typical lung carcinoid: an [18F]FDG PET/CT and SSTR imaging studyFlavia Linguanti, Elisabetta M Abenavoli, Vittorio Briganti, et al.
Oncology Research|August 24, 2006
Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedulesAlessio Tempestini, Barbara Caciagli, Maria Morganti, et al.
Medycyna Pracy|November 14, 2022
Monitoring surface contamination for thirty antineoplastic drugs: a new proposal for surface exposure levels (SELs)Stefano Dugheri, Nicola Mucci, Elisabetta Bucaletti, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2005
Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancersMaria Morganti, Monica Ciantelli, Beatrice Giglioni, et al.
JAMA Oncology|January 16, 2016
Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 TrialJulien Taieb, Aziz Zaanan, Karine Le Malicot, et al.
International Journal of Cancer|April 12, 2019
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapyEnrico Mini, Andrea Lapucci, Gabriele Perrone, et al.
European Journal of Cancer (Oxford, England : 1990)|August 19, 2008
Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)Ivan Popov, Alfredo Carrato, Alberto Sobrero, et al.
Pageof 14